fluticasone furoate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
4554 397864-44-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • fluticasone furoate
  • avamys
  • veramyst
Fluticasone furoate is a synthetic trifluorinated corticosteroid with anti‑inflammatory activity. Fluticasone furoate has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor. The precise mechanism of corticosteroid action on asthma is not known. Inflammation is an important component in the pathogenesis of asthma. Corticosteroids have been shown to have a wide range of actions on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, cytokines) involved in inflammation. These anti-inflammatory actions of corticosteroids contribute to their efficacy in asthma.
  • Molecular weight: 538.58
  • Formula: C27H29F3O6S
  • CLOGP: 4.26
  • LIPINSKI: 1
  • HAC: 6
  • HDO: 1
  • TPSA: 93.81
  • ALOGS: -4.09
  • ROTB: 6

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.20 mg N
0.11 mg N
0.60 mg Inhal.aerosol
0.60 mg Inhal.powder
1.50 mg Inhal.solution

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 4.95 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 13.40 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 10.60 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
April 27, 2007 FDA GLAXOSMITHKLINE
April 22, 2009 PMDA GlaxoSmithKline K.K.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Macular degeneration 675.23 19.55 232 14003 18676 56259156
Asthma 636.98 19.55 380 13855 112390 56165442
Wheezing 384.64 19.55 238 13997 74788 56203044
Obstructive airways disorder 364.34 19.55 144 14091 17138 56260694
Full blood count abnormal 233.54 19.55 120 14115 26342 56251490
Nasal congestion 206.21 19.55 145 14090 56225 56221607
Therapeutic product effect incomplete 158.66 19.55 163 14072 105868 56171964
Dyspnoea 143.82 19.55 399 13836 592178 55685654
Sleep disorder due to a general medical condition 125.21 19.55 56 14179 9034 56268798
Gastrooesophageal reflux disease 124.49 19.55 128 14107 83129 56194703
Bronchial haemorrhage 120.35 19.55 28 14207 529 56277303
Bronchial neoplasm 119.75 19.55 27 14208 441 56277391
Blepharospasm 110.70 19.55 39 14196 3359 56274473
Cough 109.90 19.55 218 14017 259743 56018089
Throat clearing 109.71 19.55 32 14203 1498 56276334
Nasal turbinate hypertrophy 108.45 19.55 27 14208 686 56277146
Chronic sinusitis 107.11 19.55 49 14186 8329 56269503
Chest discomfort 104.79 19.55 127 14108 98730 56179102
Bronchiectasis 104.13 19.55 53 14182 11381 56266451
Blood immunoglobulin E increased 103.65 19.55 36 14199 2973 56274859
Endometrial ablation 102.06 19.55 27 14208 878 56276954
Productive cough 101.79 19.55 96 14139 56136 56221696
Bronchial disorder 99.42 19.55 28 14207 1155 56276677
Malignant mediastinal neoplasm 87.91 19.55 24 14211 881 56276951
Rhonchi 83.72 19.55 29 14206 2375 56275457
Taste disorder 82.60 19.55 43 14192 9672 56268160
Nasal polyps 82.25 19.55 31 14204 3234 56274598
Dust allergy 82.19 19.55 21 14214 594 56277238
Sputum discoloured 79.83 19.55 48 14187 14244 56263588
Hyper IgE syndrome 78.96 19.55 19 14216 417 56277415
Respiratory tract inflammation 73.54 19.55 19 14216 562 56277270
Total lung capacity increased 72.94 19.55 21 14214 938 56276894
Dyspnoea exertional 72.65 19.55 79 14156 54610 56223222
Rhinorrhoea 71.63 19.55 80 14155 56957 56220875
Asthma-chronic obstructive pulmonary disease overlap syndrome 69.48 19.55 19 14216 702 56277130
Rhinitis 68.82 19.55 37 14198 8879 56268953
Secretion discharge 68.34 19.55 39 14196 10507 56267325
Restrictive pulmonary disease 67.35 19.55 22 14213 1504 56276328
Breath sounds abnormal 65.69 19.55 36 14199 8971 56268861
Affective disorder 63.03 19.55 30 14205 5573 56272259
Chronic obstructive pulmonary disease 61.16 19.55 74 14161 57341 56220491
Nasal obstruction 59.14 19.55 19 14216 1232 56276600
Blood test abnormal 58.92 19.55 38 14197 12746 56265086
Granuloma 57.54 19.55 28 14207 5459 56272373
Eczema 55.81 19.55 49 14186 26104 56251728
Sleep apnoea syndrome 53.96 19.55 48 14187 26013 56251819
Paraesthesia oral 52.35 19.55 37 14198 14412 56263420
Weight decreased 50.12 19.55 154 14081 240560 56037272
Haemoptysis 49.28 19.55 46 14189 26514 56251318
Procedural pain 48.42 19.55 37 14198 16234 56261598
Polycystic ovaries 47.50 19.55 21 14214 3293 56274539
Respiratory disorder 46.74 19.55 50 14185 33907 56243925
Sarcoidosis 45.85 19.55 24 14211 5456 56272376
Lung hyperinflation 43.84 19.55 15 14220 1183 56276649
Death 43.54 19.55 16 14219 341410 55936422
Toxicity to various agents 42.27 19.55 4 14231 224560 56053272
Rhinitis allergic 41.06 19.55 26 14209 8448 56269384
Epilepsy 39.85 19.55 40 14195 25191 56252641
Lactose intolerance 38.51 19.55 17 14218 2655 56275177
Forced expiratory volume decreased 37.82 19.55 20 14215 4640 56273192
Eye pruritus 37.29 19.55 30 14205 14176 56263656
Dyslipidaemia 37.19 19.55 22 14213 6331 56271501
Sinusitis 37.06 19.55 122 14113 197459 56080373
Rheumatoid arthritis 36.76 19.55 26 14209 382578 55895254
Crystal arthropathy 35.38 19.55 9 14226 250 56277582
Alopecia 35.35 19.55 15 14220 293443 55984389
Drug ineffective 35.15 19.55 370 13865 918619 55359213
Systemic lupus erythematosus 34.44 19.55 3 14232 180075 56097757
Migraine 34.39 19.55 71 14164 86726 56191106
Ear pruritus 33.92 19.55 16 14219 2912 56274920
Herpes zoster 32.35 19.55 64 14171 75825 56202007
Arthropathy 31.92 19.55 6 14229 200269 56077563
Ligament pain 31.84 19.55 8 14227 211 56277621
Rales 30.83 19.55 24 14211 10816 56267016
Dyspepsia 30.42 19.55 66 14169 83405 56194427
Sneezing 28.96 19.55 27 14208 15533 56262299
Asthmatic crisis 28.32 19.55 12 14223 1698 56276134
Ankle fracture 27.74 19.55 27 14208 16376 56261456
Bronchitis 27.29 19.55 76 14159 112235 56165597
Seasonal allergy 26.79 19.55 27 14208 17081 56260751
Paraesthesia 26.64 19.55 83 14152 130431 56147401
Glossodynia 25.53 19.55 4 14231 152454 56125378
Blood pressure diastolic abnormal 25.28 19.55 22 14213 11576 56266256
Eosinophilia 24.91 19.55 28 14207 20049 56257783
Eosinophil count increased 24.55 19.55 20 14215 9617 56268215
Blood pressure systolic increased 23.18 19.55 39 14196 40797 56237035
Sinus pain 23.14 19.55 12 14223 2676 56275156
Pertussis 23.09 19.55 8 14227 655 56277177
Loss of personal independence in daily activities 22.73 19.55 58 14177 81311 56196521
Stent placement 22.65 19.55 13 14222 3538 56274294
Sinus tachycardia 22.38 19.55 28 14207 22416 56255416
Swelling face 22.35 19.55 46 14189 56023 56221809
Chondrocalcinosis pyrophosphate 21.84 19.55 9 14226 1188 56276644
Sensitivity to weather change 21.74 19.55 16 14219 6633 56271199
Contraindicated product administered 21.66 19.55 10 14225 186276 56091556
Restless legs syndrome 21.65 19.55 24 14211 16923 56260909
Joint swelling 21.48 19.55 25 14210 289775 55988057
Angioedema 21.45 19.55 38 14197 41415 56236417
Respiratory tract infection 21.21 19.55 35 14200 36036 56241796
Subclavian vein thrombosis 21.19 19.55 10 14225 1822 56276010
Abscess 20.38 19.55 22 14213 15059 56262773
Hepatic enzyme increased 20.23 19.55 9 14226 171375 56106457
Blood pressure systolic abnormal 20.21 19.55 18 14217 9759 56268073
Blood pressure diastolic increased 20.21 19.55 17 14218 8544 56269288
Radioallergosorbent test positive 20.14 19.55 4 14231 34 56277798
Allergy to animal 20.07 19.55 8 14227 969 56276863
Pulmonary function test decreased 19.89 19.55 12 14223 3579 56274253
Thrombocytopenia 19.83 19.55 5 14230 136219 56141613
Cardiac murmur 19.72 19.55 19 14216 11382 56266450
Stress 19.68 19.55 45 14190 58865 56218967

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Asthma 367.08 19.67 180 6646 42431 31648087
Wheezing 201.08 19.67 114 6712 35872 31654646
Appendicolith 103.98 19.67 41 6785 5690 31684828
Nasal polyps 85.04 19.67 27 6799 1986 31688532
Therapeutic product effect incomplete 84.21 19.67 72 6754 43624 31646894
Appendicitis 76.78 19.67 41 6785 11424 31679094
Sleep disorder due to a general medical condition 74.60 19.67 29 6797 3873 31686645
Nasal congestion 71.35 19.67 48 6778 20333 31670185
Obstructive airways disorder 67.58 19.67 39 6787 12625 31677893
Foetal malformation 66.09 19.67 13 6813 125 31690393
Stress 58.28 19.67 46 6780 24895 31665623
Rhinitis 57.59 19.67 26 6800 5038 31685480
Seasonal allergy 55.15 19.67 26 6800 5562 31684956
Ocular discomfort 54.53 19.67 19 6807 1864 31688654
Trisomy 18 53.15 19.67 13 6813 362 31690156
Cough 53.08 19.67 100 6726 134714 31555804
Cardiogenic shock 51.65 19.67 41 6785 22367 31668151
Full blood count abnormal 51.30 19.67 36 6790 16311 31674207
Sputum discoloured 50.39 19.67 26 6800 6750 31683768
Blood phosphorus increased 47.78 19.67 22 6804 4460 31686058
Eye pruritus 45.30 19.67 22 6804 5023 31685495
Middle insomnia 41.35 19.67 22 6804 6077 31684441
Glaucoma 40.42 19.67 22 6804 6358 31684160
Ventricular fibrillation 40.28 19.67 33 6793 18815 31671703
Nasal oedema 39.58 19.67 10 6816 319 31690199
Dyspnoea 39.55 19.67 162 6664 343317 31347201
Chest discomfort 38.16 19.67 50 6776 49319 31641199
Dermatitis allergic 36.08 19.67 20 6806 5989 31684529
Eczema 35.07 19.67 28 6798 15389 31675129
Anosmia 34.47 19.67 14 6812 2094 31688424
Loss of personal independence in daily activities 34.11 19.67 36 6790 28252 31662266
Lung diffusion disorder 33.38 19.67 7 6819 95 31690423
Forced expiratory volume decreased 32.95 19.67 15 6811 2962 31687556
Chronic obstructive pulmonary disease 32.22 19.67 44 6782 45122 31645396
SARS-CoV-2 sepsis 31.68 19.67 7 6819 123 31690395
Ocular hyperaemia 31.29 19.67 22 6804 9987 31680531
Abdominal distension 31.18 19.67 46 6780 50638 31639880
Central obesity 30.93 19.67 9 6817 492 31690026
Ascites 30.85 19.67 41 6785 40972 31649546
Productive cough 30.73 19.67 37 6789 33503 31657015
Pharyngeal paraesthesia 29.97 19.67 9 6817 549 31689969
Victim of child abuse 29.51 19.67 10 6816 902 31689616
Fungal disease carrier 26.81 19.67 7 6819 255 31690263
Nasal disorder 26.59 19.67 11 6815 1724 31688794
Inguinal hernia repair 26.44 19.67 7 6819 269 31690249
Polyp 25.30 19.67 13 6813 3343 31687175
Gastroenteritis eosinophilic 24.89 19.67 6 6820 157 31690361
Nasal septum deviation 24.81 19.67 9 6817 992 31689526
Conjunctivitis 24.76 19.67 18 6808 8605 31681913
Hyponatraemia 24.45 19.67 51 6775 73748 31616770
Laryngeal discomfort 23.64 19.67 6 6820 195 31690323
Alpha 2 globulin decreased 22.61 19.67 4 6822 20 31690498
Otosalpingitis 22.61 19.67 4 6822 20 31690498
Free androgen index decreased 22.45 19.67 4 6822 21 31690497
Sex hormone binding globulin decreased 22.45 19.67 4 6822 21 31690497
Androgen insensitivity syndrome 22.29 19.67 4 6822 22 31690496
Viral acanthoma 22.29 19.67 4 6822 22 31690496
Rhinorrhoea 22.09 19.67 26 6800 22986 31667532
Testicular microlithiasis 22.00 19.67 4 6822 24 31690494
Toxicity to various agents 21.92 19.67 6 6820 181481 31509037
Dehydroepiandrosterone decreased 21.86 19.67 4 6822 25 31690493
Urine calcium/creatinine ratio increased 21.86 19.67 4 6822 25 31690493
Eosinophilic pneumonia chronic 21.82 19.67 6 6820 267 31690251
Faecal calprotectin 21.59 19.67 4 6822 27 31690491
Bronchial obstruction 21.51 19.67 9 6817 1451 31689067
Rhinitis allergic 21.35 19.67 11 6815 2843 31687675
Cortisol decreased 21.26 19.67 8 6818 977 31689541
Sinusitis 20.70 19.67 32 6794 36664 31653854
Blue toe syndrome 20.41 19.67 5 6821 140 31690378
Blood test abnormal 20.37 19.67 14 6812 6127 31684391
Oropharyngeal candidiasis 20.18 19.67 7 6819 677 31689841

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Asthma 843.94 17.28 476 18415 120317 70789236
Wheezing 519.62 17.28 319 18572 93851 70815702
Obstructive airways disorder 381.04 17.28 170 18721 25943 70883610
Full blood count abnormal 278.36 17.28 149 18742 33729 70875824
Nasal congestion 264.87 17.28 183 18708 65489 70844064
Therapeutic product effect incomplete 208.92 17.28 205 18686 119677 70789876
Sleep disorder due to a general medical condition 161.71 17.28 71 18820 10405 70899148
Dyspnoea 154.82 17.28 502 18389 769558 70139995
Nasal polyps 148.91 17.28 53 18838 4463 70905090
Cough 148.05 17.28 290 18601 325087 70584466
Rhinitis 124.40 17.28 61 18830 11486 70898067
Chest discomfort 122.37 17.28 158 18733 124223 70785330
Productive cough 119.94 17.28 125 18766 78212 70831341
Gastrooesophageal reflux disease 119.89 17.28 134 18757 90705 70818848
Bronchial neoplasm 117.90 17.28 27 18864 449 70909104
Sputum discoloured 116.95 17.28 69 18822 18782 70890771
Nasal turbinate hypertrophy 116.32 17.28 28 18863 583 70908970
Throat clearing 108.80 17.28 33 18858 1678 70907875
Endometrial ablation 102.66 17.28 27 18864 813 70908740
Chronic sinusitis 101.18 17.28 48 18843 8403 70901150
Bronchiectasis 100.06 17.28 59 18832 16038 70893515
Blepharospasm 96.78 17.28 37 18854 3808 70905745
Bronchial haemorrhage 96.08 17.28 28 18863 1239 70908314
Rhonchi 94.98 17.28 36 18855 3619 70905934
Appendicolith 92.55 17.28 40 18851 5640 70903913
Blood immunoglobulin E increased 89.25 17.28 37 18854 4707 70904846
Rhinorrhoea 87.69 17.28 98 18793 66273 70843280
Malignant mediastinal neoplasm 82.86 17.28 23 18868 852 70908701
Eczema 80.66 17.28 69 18822 33712 70875841
Blood test abnormal 79.13 17.28 49 18842 14541 70895012
Bronchial disorder 79.02 17.28 28 18863 2326 70907227
Chronic obstructive pulmonary disease 76.88 17.28 99 18792 77542 70832011
Restrictive pulmonary disease 75.78 17.28 27 18864 2279 70907274
Hyper IgE syndrome 75.51 17.28 19 18872 478 70909075
Taste disorder 74.11 17.28 43 18848 11342 70898211
Toxicity to various agents 71.19 17.28 9 18882 382163 70527390
Stress 70.98 17.28 89 18802 67877 70841676
Total lung capacity increased 67.77 17.28 20 18871 925 70908628
Dust allergy 67.50 17.28 21 18870 1163 70908390
Eye pruritus 66.55 17.28 44 18847 14603 70894950
Respiratory tract inflammation 65.74 17.28 19 18872 816 70908737
Forced expiratory volume decreased 65.20 17.28 34 18857 7280 70902273
Affective disorder 64.49 17.28 34 18857 7445 70902108
Breath sounds abnormal 63.18 17.28 41 18850 13190 70896363
Secretion discharge 61.56 17.28 40 18851 12893 70896660
Macular degeneration 61.46 17.28 33 18858 7495 70902058
Sleep apnoea syndrome 56.96 17.28 56 18835 32657 70876896
Seasonal allergy 55.27 17.28 38 18853 13446 70896107
Paraesthesia oral 55.20 17.28 40 18851 15377 70894176
Sinusitis 55.13 17.28 132 18759 169063 70740490
Respiratory disorder 53.78 17.28 59 18832 39064 70870489
Nasal obstruction 53.62 17.28 19 18872 1578 70907975
Dyspnoea exertional 52.50 17.28 83 18808 78347 70831206
Appendicitis 52.27 17.28 40 18851 16693 70892860
Granuloma 49.91 17.28 29 18862 7666 70901887
Rhinitis allergic 49.85 17.28 31 18860 9264 70900289
Polycystic ovaries 49.34 17.28 21 18870 2851 70906702
Asthma-chronic obstructive pulmonary disease overlap syndrome 46.48 17.28 17 18874 1547 70908006
Loss of personal independence in daily activities 45.05 17.28 81 18810 84829 70824724
Middle insomnia 44.79 17.28 34 18857 14019 70895534
Weight decreased 44.53 17.28 182 18709 310306 70599247
Migraine 43.66 17.28 73 18818 72165 70837388
Anosmia 41.53 17.28 22 18869 4861 70904692
Lung hyperinflation 41.31 17.28 16 18875 1705 70907848
Lactose intolerance 41.16 17.28 17 18874 2141 70907412
Procedural pain 39.38 17.28 35 18856 17974 70891579
Death 37.08 17.28 49 18842 510012 70399541
Anaemia 36.84 17.28 32 18859 403391 70506162
Bronchitis 36.59 17.28 90 18801 117153 70792400
Acute kidney injury 35.11 17.28 45 18846 474579 70434974
Blood phosphorus increased 34.85 17.28 22 18869 6748 70902805
Polyp 33.69 17.28 22 18869 7148 70902405
Blood pressure diastolic increased 33.07 17.28 27 18864 12364 70897189
Sarcoidosis 32.78 17.28 21 18870 6606 70902947
Ear pruritus 32.41 17.28 16 18875 3054 70906499
Thrombocytopenia 31.73 17.28 12 18879 239098 70670455
Herpes zoster 31.59 17.28 70 18821 85165 70824388
Epilepsy 31.59 17.28 45 18846 38739 70870814
Cardiac murmur 31.36 17.28 26 18865 12160 70897393
Haemoptysis 31.09 17.28 52 18839 51400 70858153
Lower respiratory tract infection 30.86 17.28 82 18809 111831 70797722
Nasal oedema 30.83 17.28 12 18879 1295 70908258
Swelling face 30.65 17.28 58 18833 63106 70846447
Ligament pain 30.16 17.28 8 18883 249 70909304
SARS-CoV-2 sepsis 30.04 17.28 7 18884 126 70909427
Ankle fracture 29.99 17.28 28 18863 15316 70894237
Dyslipidaemia 29.55 17.28 23 18868 9837 70899716
Eosinophilic pneumonia chronic 29.31 17.28 9 18882 477 70909076
Lung diffusion disorder 29.30 17.28 7 18884 141 70909412
Dehydration 28.93 17.28 12 18879 226130 70683423
Cardiogenic shock 27.92 17.28 41 18850 36266 70873287
Sneezing 27.63 17.28 28 18863 16923 70892630
Eosinophilia 27.42 17.28 43 18848 40276 70869277
Dyspepsia 27.38 17.28 68 18823 89009 70820544
Victim of child abuse 27.15 17.28 10 18881 928 70908625
Ocular discomfort 27.08 17.28 16 18875 4361 70905192
Cardiac arrest 26.90 17.28 5 18886 159829 70749724
Asthmatic crisis 26.60 17.28 12 18879 1872 70907681
Haemoglobin decreased 26.06 17.28 11 18880 205148 70704405
Paraesthesia 25.50 17.28 91 18800 145446 70764107
Treatment failure 25.38 17.28 4 18887 144138 70765415
Inguinal hernia repair 25.10 17.28 7 18884 264 70909289
Fungal disease carrier 24.16 17.28 7 18884 303 70909250
Blood pressure diastolic abnormal 24.16 17.28 25 18866 15479 70894074
Synovitis 24.13 17.28 3 18888 129225 70780328
Neutropenia 23.93 17.28 20 18871 257136 70652417
Atopy 23.86 17.28 7 18884 317 70909236
Sensitivity to weather change 23.78 17.28 18 18873 7387 70902166
Platelet count decreased 23.54 17.28 9 18882 178213 70731340
Eosinophilic granulomatosis with polyangiitis 23.23 17.28 13 18878 3200 70906353
Throat irritation 23.11 17.28 37 18854 35267 70874286
Oropharyngeal pain 23.02 17.28 67 18824 96243 70813310
Ventricular fibrillation 22.88 17.28 32 18859 27079 70882474
Eosinophil count increased 22.74 17.28 24 18867 15198 70894355
Blood pressure systolic increased 22.32 17.28 48 18843 57211 70852342
Rheumatoid arthritis 22.24 17.28 27 18864 291778 70617775
Ovarian cyst 22.08 17.28 21 18870 11751 70897802
Overdose 21.72 17.28 9 18882 169736 70739817
Gastrointestinal haemorrhage 21.67 17.28 5 18886 137403 70772150
Respiratory failure 21.50 17.28 9 18882 168726 70740827
Cardiac failure congestive 21.22 17.28 5 18886 135452 70774101
Crepitations 21.20 17.28 18 18873 8696 70900857
Gastroenteritis eosinophilic 21.17 17.28 6 18885 240 70909313
Pertussis 20.67 17.28 8 18883 851 70908702
Respiratory tract infection 20.65 17.28 39 18852 42359 70867194
Rales 20.41 17.28 24 18867 17111 70892442
Cortisol decreased 20.31 17.28 10 18881 1897 70907656
White blood cell count decreased 20.24 17.28 10 18881 170131 70739422
Nasal disorder 20.20 17.28 12 18879 3302 70906251
Febrile neutropenia 20.13 17.28 15 18876 204303 70705250
Sinus disorder 20.05 17.28 25 18866 18934 70890619
Radioallergosorbent test positive 20.04 17.28 4 18887 33 70909520
Joint swelling 19.75 17.28 23 18868 253188 70656365
Asthenia 19.47 17.28 60 18831 457606 70451947
Drug interaction 19.23 17.28 46 18845 381395 70528158
Ocular hyperaemia 19.20 17.28 28 18863 24611 70884942
Autism spectrum disorder 18.97 17.28 8 18883 1062 70908491
Central obesity 18.86 17.28 9 18882 1594 70907959
Pharyngeal paraesthesia 18.82 17.28 10 18881 2222 70907331
Diarrhoea 18.77 17.28 127 18764 783214 70126339
Sinus pain 18.42 17.28 11 18880 3058 70906495
Influenza 18.15 17.28 69 18822 113631 70795922
Malignant neoplasm progression 18.10 17.28 5 18886 121734 70787819
Eosinophilic bronchitis 18.09 17.28 6 18885 408 70909145
Hypotension 17.92 17.28 52 18839 404329 70505224
Septic shock 17.87 17.28 4 18887 112254 70797299
Illness 17.71 17.28 31 18860 31760 70877793
Lung neoplasm malignant 17.68 17.28 27 18864 24715 70884838
Restless legs syndrome 17.44 17.28 23 18868 18405 70891148

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC D07AC17 DERMATOLOGICALS
CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
CORTICOSTEROIDS, PLAIN
Corticosteroids, potent (group III)
ATC R01AD08 RESPIRATORY SYSTEM
NASAL PREPARATIONS
DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
Corticosteroids
ATC R01AD12 RESPIRATORY SYSTEM
NASAL PREPARATIONS
DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
Corticosteroids
ATC R01AD58 RESPIRATORY SYSTEM
NASAL PREPARATIONS
DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
Corticosteroids
ATC R03AK06 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
ADRENERGICS, INHALANTS
Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics
ATC R03AK10 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
ADRENERGICS, INHALANTS
Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics
ATC R03AK11 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
ADRENERGICS, INHALANTS
Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics
ATC R03AL08 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
ADRENERGICS, INHALANTS
Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
ATC R03BA05 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS
Glucocorticoids
ATC R03BA09 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS
Glucocorticoids
FDA MoA N0000175450 Corticosteroid Hormone Receptor Agonists
FDA EPC N0000175576 Corticosteroid
CHEBI has role CHEBI:49167 anti-asthmatic drugs
CHEBI has role CHEBI:50857 anti-allergic drugs
MeSH PA D018926 Anti-Allergic Agents
MeSH PA D018927 Anti-Asthmatic Agents
MeSH PA D000893 Anti-Inflammatory Agents
MeSH PA D001993 Bronchodilator Agents
MeSH PA D003879 Dermatologic Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D019141 Respiratory System Agents
CHEBI has role CHEBI:50266 Prodrugs

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Chronic obstructive lung disease indication 13645005 DOID:3083
Allergic rhinitis indication 61582004
Chronic bronchitis indication 63480004 DOID:6132
Pulmonary emphysema indication 87433001
Asthma indication 195967001 DOID:2841
Chronic Non-Allergic Rhinitis indication
Mycosis contraindication 3218000 DOID:1564
Ocular hypertension contraindication 4210003 DOID:9282
Epistaxis contraindication 12441001
Measles contraindication 14189004 DOID:8622
Disease caused by parasite contraindication 17322007
Glaucoma contraindication 23986001 DOID:1686
Viral disease contraindication 34014006 DOID:934
Hypercortisolism contraindication 47270006
Perforation of nasal septum contraindication 80142000
Bacterial infectious disease contraindication 87628006
Operation on nose contraindication 88733004
Bilateral cataracts contraindication 95722004
Pulmonary tuberculosis contraindication 154283005 DOID:2957
Ophthalmic herpes simplex contraindication 186542001
Varicella-zoster virus infection contraindication 309465005
Adrenal cortical hypofunction contraindication 386584007 DOID:10493
Exposure to varicella contraindication 444453009
Nasal Candidiasis contraindication
Nasal Trauma contraindication
Nasal Septal Ulcers contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.49 acidic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
0.1MG/INH;EQ 0.025MG BASE/INH BREO ELLIPTA GLAXO GRP LTD N204275 May 10, 2013 RX POWDER INHALATION RE44874 March 23, 2023 FOR THE LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS
0.1MG/INH;EQ 0.025MG BASE/INH BREO ELLIPTA GLAXO GRP LTD N204275 May 10, 2013 RX POWDER INHALATION RE44874 March 23, 2023 INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER
0.2MG/INH;EQ 0.025MG BASE/INH BREO ELLIPTA GLAXO GRP LTD N204275 April 30, 2015 RX POWDER INHALATION RE44874 March 23, 2023 INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER
0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH TRELEGY ELLIPTA GLAXOSMITHKLINE N209482 Sept. 18, 2017 RX POWDER INHALATION RE44874 March 23, 2023 INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA
0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH TRELEGY ELLIPTA GLAXOSMITHKLINE N209482 Sept. 18, 2017 RX POWDER INHALATION RE44874 March 23, 2023 INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA; AND ASTHMA
0.2MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH TRELEGY ELLIPTA GLAXOSMITHKLINE N209482 Sept. 9, 2020 RX POWDER INHALATION RE44874 March 23, 2023 INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA; AND ASTHMA
0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH TRELEGY ELLIPTA GLAXOSMITHKLINE N209482 Sept. 18, 2017 RX POWDER INHALATION 8309572 April 27, 2025 METHOD OF INHIBITING THE BINDING OF ACETYLCHOLINE TO AN ACETYLCHOLINE RECEPTOR IN THE RESPIRATORY TRACT OF A HUMAN, COMPRISING CONTACTING THE RECEPTOR WITH AN EFFECTIVE AMOUNT OF UMECLIDINIUM, VIA TOPICAL APPLICATION
0.2MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH TRELEGY ELLIPTA GLAXOSMITHKLINE N209482 Sept. 9, 2020 RX POWDER INHALATION 8309572 April 27, 2025 METHOD OF INHIBITING THE BINDING OF ACETYLCHOLINE TO AN ACETYLCHOLINE RECEPTOR IN THE RESPIRATORY TRACT OF A HUMAN, COMPRISING CONTACTING THE RECEPTOR WITH AN EFFECTIVE AMOUNT OF UMECLIDINIUM, VIA TOPICAL APPLICATION
0.1MG/INH;EQ 0.025MG BASE/INH BREO ELLIPTA GLAXO GRP LTD N204275 May 10, 2013 RX POWDER INHALATION 7439393 May 21, 2025 INDICATED FOR LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PTS WITH A HISTORY OF EXACERBATIONS
0.1MG/INH;EQ 0.025MG BASE/INH BREO ELLIPTA GLAXO GRP LTD N204275 May 10, 2013 RX POWDER INHALATION 7439393 May 21, 2025 INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING BRONCHITIS AND/OR EMPHYSEMA
0.1MG/INH;EQ 0.025MG BASE/INH BREO ELLIPTA GLAXO GRP LTD N204275 May 10, 2013 RX POWDER INHALATION 7439393 May 21, 2025 INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER
0.1MG/INH;EQ 0.025MG BASE/INH BREO ELLIPTA GLAXO GRP LTD N204275 May 10, 2013 RX POWDER INHALATION 7439393 May 21, 2025 INDICATED FOR THE ONCE-DAILY TREATMENT OF ASTHMA IN PATIENTS 18 YEARS AND OLDER
0.2MG/INH;EQ 0.025MG BASE/INH BREO ELLIPTA GLAXO GRP LTD N204275 April 30, 2015 RX POWDER INHALATION 7439393 May 21, 2025 INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING BRONCHITIS AND/OR EMPHYSEMA
0.2MG/INH;EQ 0.025MG BASE/INH BREO ELLIPTA GLAXO GRP LTD N204275 April 30, 2015 RX POWDER INHALATION 7439393 May 21, 2025 INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER
0.2MG/INH;EQ 0.025MG BASE/INH BREO ELLIPTA GLAXO GRP LTD N204275 April 30, 2015 RX POWDER INHALATION 7439393 May 21, 2025 INDICATED FOR THE ONCE-DAILY TREATMENT OF ASTHMA IN PATIENTS 18 YEARS AND OLDER
0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH TRELEGY ELLIPTA GLAXOSMITHKLINE N209482 Sept. 18, 2017 RX POWDER INHALATION 7439393 May 21, 2025 INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA
0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH TRELEGY ELLIPTA GLAXOSMITHKLINE N209482 Sept. 18, 2017 RX POWDER INHALATION 7439393 May 21, 2025 MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 18 YRS AND OLDER, OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA
0.2MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH TRELEGY ELLIPTA GLAXOSMITHKLINE N209482 Sept. 9, 2020 RX POWDER INHALATION 7439393 May 21, 2025 MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 18 YRS AND OLDER, OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA
0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH TRELEGY ELLIPTA GLAXOSMITHKLINE N209482 Sept. 18, 2017 RX POWDER INHALATION 8183257 July 27, 2025 METHOD OF INHIBITING THE BINDING OF ACETYLCHOLINE TO AN ACETYLCHOLINE RECEPTOR IN THE RESPIRATORY TRACT OF A HUMAN, COMPRISING CONTACTING THE RECEPTOR WITH AN EFFECTIVE AMOUNT OF UMECLIDINIUM, VIA INHALATION
0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH TRELEGY ELLIPTA GLAXOSMITHKLINE N209482 Sept. 18, 2017 RX POWDER INHALATION 8183257 July 27, 2025 METHOD OF INHIBITING THE BINDING OF ACETYLCHOLINE TO AN ACETYLCHOLINE RECEPTOR IN THE RESPIRATORY TRACT OF A HUMAN, COMPRISING CONTACTING THE RECEPTOR WITH AN EFFECTIVE AMOUNT OF UMECLIDINIUM, VIA TOPICAL APPLICATION
0.2MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH TRELEGY ELLIPTA GLAXOSMITHKLINE N209482 Sept. 9, 2020 RX POWDER INHALATION 8183257 July 27, 2025 METHOD OF INHIBITING THE BINDING OF ACETYLCHOLINE TO AN ACETYLCHOLINE RECEPTOR IN THE RESPIRATORY TRACT OF A HUMAN, COMPRISING CONTACTING THE RECEPTOR WITH AN EFFECTIVE AMOUNT OF UMECLIDINIUM, VIA TOPICAL APPLICATION
0.1MG/INH;EQ 0.025MG BASE/INH BREO ELLIPTA GLAXO GRP LTD N204275 May 10, 2013 RX POWDER INHALATION 8511304 June 14, 2027 INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER
0.1MG/INH;EQ 0.025MG BASE/INH BREO ELLIPTA GLAXO GRP LTD N204275 May 10, 2013 RX POWDER INHALATION 8511304 June 14, 2027 LONG-TERM, ONCE DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS
0.2MG/INH;EQ 0.025MG BASE/INH BREO ELLIPTA GLAXO GRP LTD N204275 April 30, 2015 RX POWDER INHALATION 8511304 June 14, 2027 INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER
0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH TRELEGY ELLIPTA GLAXOSMITHKLINE N209482 Sept. 18, 2017 RX POWDER INHALATION 8511304 June 14, 2027 METHOD OF DISPENSING A COMBINATION MEDICAMENT PRODUCT FROM CLAIMED DELIVERY DEVICE, FOR EXAMPLE FOR THE TREATMENT OF ASTHMA OR COPD
0.2MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH TRELEGY ELLIPTA GLAXOSMITHKLINE N209482 Sept. 9, 2020 RX POWDER INHALATION 8511304 June 14, 2027 METHOD OF DISPENSING A COMBINATION MEDICAMENT PRODUCT FROM CLAIMED DELIVERY DEVICE, FOR EXAMPLE FOR THE TREATMENT OF ASTHMA OR COPD
0.1MG/INH;EQ 0.025MG BASE/INH BREO ELLIPTA GLAXO GRP LTD N204275 May 10, 2013 RX POWDER INHALATION 11116721 Feb. 26, 2029 INDICATED FOR LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PTS WITH A HISTORY OF EXACERBATIONS
0.1MG/INH;EQ 0.025MG BASE/INH BREO ELLIPTA GLAXO GRP LTD N204275 May 10, 2013 RX POWDER INHALATION 11116721 Feb. 26, 2029 INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER
0.2MG/INH;EQ 0.025MG BASE/INH BREO ELLIPTA GLAXO GRP LTD N204275 April 30, 2015 RX POWDER INHALATION 11116721 Feb. 26, 2029 INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER
0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH TRELEGY ELLIPTA GLAXOSMITHKLINE N209482 Sept. 18, 2017 RX POWDER INHALATION 11090294 Nov. 29, 2030 MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) COMPRISING THE ONCE PER DAY ADMINISTRATION OF TRELEGY ELLIPTA, 100 MCG FLUTICASONE FUROATE/62.5 MCG UMECLIDINIUM/25 MCG VILANTEROL

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH TRELEGY ELLIPTA GLAXOSMITHKLINE N209482 Sept. 18, 2017 RX POWDER INHALATION Sept. 9, 2023 MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS AGED 18 YEARS AND OLDER
0.2MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH TRELEGY ELLIPTA GLAXOSMITHKLINE N209482 Sept. 9, 2020 RX POWDER INHALATION Sept. 9, 2023 NEW STRENGTH

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Glucocorticoid receptor Nuclear hormone receptor AGONIST IC50 10.12 CHEMBL CHEMBL
Mineralocorticoid receptor Nuclear hormone receptor IC50 6.83 CHEMBL
Progesterone receptor Nuclear hormone receptor IC50 7.68 CHEMBL
Androgen receptor Transcription factor IC50 5.73 CHEMBL
Glucocorticoid receptor Transcription factor IC50 8.30 CHEMBL

External reference:

IDSource
D06315 KEGG_DRUG
4026165 VUID
N0000179800 NUI
4020529 VANDF
4026165 VANDF
CHEBI:74899 CHEBI
CHEBI:5134 CHEBI
GW6 PDB_CHEM_ID
CHEMBL1676 ChEMBL_ID
C523187 MESH_SUPPLEMENTAL_RECORD_UI
10892 IUPHAR_LIGAND_ID
6699 IUPHAR_LIGAND_ID
8521 INN_ID
DB08906 DRUGBANK_ID
JS86977WNV UNII
DB13867 DRUGBANK_ID
41126 RXNORM
109674 MMSL
23848 MMSL
51966 MMSL
d01296 MMSL
004952 NDDF
012173 NDDF
108632003 SNOMEDCT_US
397192001 SNOMEDCT_US
426409006 SNOMEDCT_US
C1948374 UMLSCUI
C0082607 UMLSCUI
CHEMBL1201396 ChEMBL_ID
9854489 PUBCHEM_CID
5636 INN_ID
90566-53-3 SECONDARY_CAS_RN
D000068298 MESH_DESCRIPTOR_UI
5311101 PUBCHEM_CID
CUT2W21N7U UNII

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
FLONASE SENSIMISTALLERGY RELIEF HUMAN OTC DRUG LABEL 1 0135-0615 SPRAY, METERED 27.50 ug NASAL NDA 16 sections
FLONASE SENSIMISTALLERGY RELIEF HUMAN OTC DRUG LABEL 1 0135-0616 SPRAY, METERED 27.50 ug NASAL NDA 16 sections
Breo Ellipta HUMAN PRESCRIPTION DRUG LABEL 2 0173-0859 POWDER 100 ug RESPIRATORY (INHALATION) NDA 26 sections
Breo Ellipta HUMAN PRESCRIPTION DRUG LABEL 2 0173-0859 POWDER 100 ug RESPIRATORY (INHALATION) NDA 26 sections
Arnuity Ellipta HUMAN PRESCRIPTION DRUG LABEL 1 0173-0874 POWDER 100 ug RESPIRATORY (INHALATION) NDA 27 sections
Arnuity Ellipta HUMAN PRESCRIPTION DRUG LABEL 1 0173-0874 POWDER 100 ug RESPIRATORY (INHALATION) NDA 27 sections
Arnuity Ellipta HUMAN PRESCRIPTION DRUG LABEL 1 0173-0876 POWDER 200 ug RESPIRATORY (INHALATION) NDA 27 sections
Arnuity Ellipta HUMAN PRESCRIPTION DRUG LABEL 1 0173-0876 POWDER 200 ug RESPIRATORY (INHALATION) NDA 27 sections
Breo Ellipta HUMAN PRESCRIPTION DRUG LABEL 2 0173-0882 POWDER 200 ug RESPIRATORY (INHALATION) NDA 26 sections
Breo Ellipta HUMAN PRESCRIPTION DRUG LABEL 2 0173-0882 POWDER 200 ug RESPIRATORY (INHALATION) NDA 26 sections
Trelegy Ellipta HUMAN PRESCRIPTION DRUG LABEL 3 0173-0887 POWDER 100 ug RESPIRATORY (INHALATION) NDA 27 sections
Trelegy Ellipta HUMAN PRESCRIPTION DRUG LABEL 3 0173-0887 POWDER 100 ug RESPIRATORY (INHALATION) NDA 27 sections
Arnuity Ellipta HUMAN PRESCRIPTION DRUG LABEL 1 0173-0888 POWDER 50 ug RESPIRATORY (INHALATION) NDA 27 sections
Arnuity Ellipta HUMAN PRESCRIPTION DRUG LABEL 1 0173-0888 POWDER 50 ug RESPIRATORY (INHALATION) NDA 27 sections
Trelegy Ellipta HUMAN PRESCRIPTION DRUG LABEL 3 0173-0893 POWDER 200 ug RESPIRATORY (INHALATION) NDA 27 sections
Trelegy Ellipta HUMAN PRESCRIPTION DRUG LABEL 3 0173-0893 POWDER 200 ug RESPIRATORY (INHALATION) NDA 27 sections
FLONASE SENSIMISTALLERGY RELIEF HUMAN OTC DRUG LABEL 1 50090-5967 SPRAY, METERED 27.50 ug NASAL NDA 17 sections
FLONASE SENSIMISTALLERGY RELIEF HUMAN OTC DRUG LABEL 1 50090-6075 SPRAY, METERED 27.50 ug NASAL NDA 17 sections
Veramyst HUMAN PRESCRIPTION DRUG LABEL 1 54868-6168 SPRAY, METERED 27.50 ug NASAL NDA 27 sections
Fluticasone Furoate and Vilanterol HUMAN PRESCRIPTION DRUG LABEL 2 66993-135 POWDER 100 ug RESPIRATORY (INHALATION) NDA authorized generic 26 sections
Fluticasone Furoate and Vilanterol HUMAN PRESCRIPTION DRUG LABEL 2 66993-136 POWDER 200 ug RESPIRATORY (INHALATION) NDA authorized generic 26 sections
Breo Ellipta HUMAN PRESCRIPTION DRUG LABEL 2 70518-2028 POWDER 100 ug RESPIRATORY (INHALATION) NDA 27 sections
Breo Ellipta HUMAN PRESCRIPTION DRUG LABEL 2 70518-2028 POWDER 100 ug RESPIRATORY (INHALATION) NDA 27 sections